Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.
View details for DOI 10.1016/j.hoc.2013.10.004
View details for Web of Science ID 000329086300010
View details for PubMedID 24287071
View details for PubMedCentralID PMC4023679